Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06936527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Study acronym: XS-03-II201
StatusEnrolling by Invitation
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: NovaOnco Therapeutics Co., Ltd. to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    • Eligibility criteria expanded, about 49 words
    • Secondary endpoints: details revised at 3 of 15 entries
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Jun 30, 2025 to May 23, 2025
    • Site contact updated
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
Trial Details
NCT Number NCT06936527
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions
(from sponsor)		 Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation
Related terms Colorectal Neoplasms
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov